Bayer Pharmaceuticals

• The Cardiometabolic Effects of Menopause

  Consulting or advice, 4 Sept 2026

• Obesity and Women's health across the lifespan: A clinical review of life Stage-Specific challenges and treatment considerations

  Consulting or advice, 14 Aug 2026

• Bone mineral density in women with functional hypothalamic amenorrhea compared to eumenorrheic controls and recently menopausal women

  Consulting or advice, 4 Aug 2026

• Muscle Mass and Glucagon-Like Peptide-1 Receptor Agonists: Adaptive or Maladaptive Response to Weight Loss?

  Consulting or advice, Fees or honoraria, 14 Oct 2024

Sources: pubmed.ncbi.nlm.nih.gov

• Retrospective Effects of GLP-1 Receptor Agonists with and without Concomitant SGLT2 Inhibitor Use in Diabetic Renal Transplant Recipients after 12 Months

  ADA Scientific Sessions 2025 abstract, 13 Jun 2025

• Enhanced Renal Protective Effects of Tirzepatide in T2D People

  ADA Scientific Sessions 2025 abstract, 13 Jun 2025

• Diabetic Peripheral Neuropathy as a Risk Factor for Brain Disease

  ADA Scientific Sessions 2025 abstract, 13 Jun 2025

• Clinical Implementation of Polygenic Risk Scores for Cardio-Renal-Metabolic Disease—Uptake and Impact in a Large Community Health System

  ADA Scientific Sessions 2025 abstract, 13 Jun 2025

• Systematic Review and Meta-analysis of the Association of SGLT2 Inhibitors and GLP-1 Receptor Agonists on the Risk of Dementia in Patients with Type 2 Diabetes

  ADA Scientific Sessions 2025 abstract, 13 Jun 2025

• Body Composition and Body Mass Index among People with and without Diabetes—A National Analysis, 2011–2018

  ADA Scientific Sessions 2025 abstract, 13 Jun 2025

• Diabetes Prediction without Blood Tests—The Role of Retinal Imaging and Artificial Intelligence

  ADA Scientific Sessions 2025 abstract, 13 Jun 2025

• Five-Year Changes in Glucose Tolerance, Insulin Secretion, and Insulin Resistance in Community-Dwelling Older Adults

  ADA Scientific Sessions 2025 abstract, 13 Jun 2025